175 related articles for article (PubMed ID: 27338099)
21. Selection of Epstein-Barr virus specific cytotoxic T lymphocytes can be performed with B lymphoblastoid cell lines created in serum-free media.
Gallot G; Vollant S; Vivien R; Clémenceau B; Ferrand C; Tiberghien P; Gaschet J; Robillard N; Vié H
Clin Exp Immunol; 2006 Apr; 144(1):158-68. PubMed ID: 16542378
[TBL] [Abstract][Full Text] [Related]
22. CD8+ T cells retain protective functions despite sustained inhibitory receptor expression during Epstein-Barr virus infection in vivo.
Chatterjee B; Deng Y; Holler A; Nunez N; Azzi T; Vanoaica LD; Müller A; Zdimerova H; Antsiferova O; Zbinden A; Capaul R; Dreyer JH; Nadal D; Becher B; Robinson MD; Stauss H; Münz C
PLoS Pathog; 2019 May; 15(5):e1007748. PubMed ID: 31145756
[TBL] [Abstract][Full Text] [Related]
23. T cells or active Epstein-Barr virus infection in the development of lymphoproliferative disease in human B cell-injected severe combined immunodeficient mice.
Coles RE; Boyle TJ; DiMaio JM; Berend KR; Via DF; Lyerly HK
Ann Surg Oncol; 1994 Sep; 1(5):405-10. PubMed ID: 7531601
[TBL] [Abstract][Full Text] [Related]
24. HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2.
Lee SP; Thomas WA; Murray RJ; Khanim F; Kaur S; Young LS; Rowe M; Kurilla M; Rickinson AB
J Virol; 1993 Dec; 67(12):7428-35. PubMed ID: 7693972
[TBL] [Abstract][Full Text] [Related]
25. Increased T-cell responses to Epstein-Barr virus with high viral load in patients with Epstein-Barr virus-positive diffuse large B-cell lymphoma.
Morishima S; Nakamura S; Yamamoto K; Miyauchi H; Kagami Y; Kinoshita T; Onoda H; Yatabe Y; Ito M; Miyamura K; Nagai H; Moritani S; Sugiura I; Tsushita K; Mihara H; Ohbayashi K; Iba S; Emi N; Okamoto M; Iwata S; Kimura H; Kuzushima K; Morishima Y
Leuk Lymphoma; 2015 Apr; 56(4):1072-8. PubMed ID: 24975317
[TBL] [Abstract][Full Text] [Related]
26. Cytolytic T cell reactivity to Epstein-Barr virus is lost during in vitro T cell expansion.
Carlens S; Liu D; Ringdén O; Aschan J; Christensson B; Levitsky V; Dilber MS
J Hematother Stem Cell Res; 2002 Aug; 11(4):669-74. PubMed ID: 12201955
[TBL] [Abstract][Full Text] [Related]
27. Plasmacytoid differentiation of Epstein-Barr virus-transformed B cells in vivo is associated with reduced expression of viral latent genes.
Rochford R; Hobbs MV; Garnier JL; Cooper NR; Cannon MJ
Proc Natl Acad Sci U S A; 1993 Jan; 90(1):352-6. PubMed ID: 8380497
[TBL] [Abstract][Full Text] [Related]
28. Impaired cytotoxic T lymphocyte response to Epstein-Barr virus-infected NK cells in patients with severe chronic active EBV infection.
Tsuge I; Morishima T; Kimura H; Kuzushima K; Matsuoka H
J Med Virol; 2001 Jun; 64(2):141-8. PubMed ID: 11360246
[TBL] [Abstract][Full Text] [Related]
29. Analysis of MAGE-3 derived synthetic peptide as a human lung cancer antigen recognized by cytotoxic T lymphocytes.
Eifuku R; Takenoyama M; Yoshino I; Imahayashi S; So T; Yasuda M; Sugaya M; Yasumoto K
Int J Clin Oncol; 2001 Feb; 6(1):34-9. PubMed ID: 11706525
[TBL] [Abstract][Full Text] [Related]
30. Epstein-Barr virus-specific cytotoxic T-cell recognition of transfectants expressing the virus-coded latent membrane protein LMP.
Murray RJ; Wang D; Young LS; Wang F; Rowe M; Kieff E; Rickinson AB
J Virol; 1988 Oct; 62(10):3747-55. PubMed ID: 2843672
[TBL] [Abstract][Full Text] [Related]
31. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
Niller HH; Wolf H; Minarovits J
Autoimmunity; 2008 May; 41(4):298-328. PubMed ID: 18432410
[TBL] [Abstract][Full Text] [Related]
32. A mouse monoclonal antibody against Epstein-Barr virus envelope glycoprotein 350 prevents infection both in vitro and in vivo.
Haque T; Johannessen I; Dombagoda D; Sengupta C; Burns DM; Bird P; Hale G; Mieli-Vergani G; Crawford DH
J Infect Dis; 2006 Sep; 194(5):584-7. PubMed ID: 16897655
[TBL] [Abstract][Full Text] [Related]
33. Identification of a cytotoxic T-lymphocyte response to the novel BARF0 protein of Epstein-Barr virus: a critical role for antigen expression.
Kienzle N; Sculley TB; Poulsen L; Buck M; Cross S; Raab-Traub N; Khanna R
J Virol; 1998 Aug; 72(8):6614-20. PubMed ID: 9658107
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic efficacy of an Fc-enhanced TCR-like antibody to the intracellular WT1 oncoprotein.
Veomett N; Dao T; Liu H; Xiang J; Pankov D; Dubrovsky L; Whitten JA; Park SM; Korontsvit T; Zakhaleva V; Casey E; Curcio M; Kharas MG; O'Reilly RJ; Liu C; Scheinberg DA
Clin Cancer Res; 2014 Aug; 20(15):4036-46. PubMed ID: 24850840
[TBL] [Abstract][Full Text] [Related]
35. Experimental infection of NOD/SCID mice reconstituted with human CD34+ cells with Epstein-Barr virus.
Islas-Ohlmayer M; Padgett-Thomas A; Domiati-Saad R; Melkus MW; Cravens PD; Martin Mdel P; Netto G; Garcia JV
J Virol; 2004 Dec; 78(24):13891-900. PubMed ID: 15564497
[TBL] [Abstract][Full Text] [Related]
36. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
Loomis R; Carbone R; Reiss M; Lacy J
Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752
[TBL] [Abstract][Full Text] [Related]
37. Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy.
Wang Y; Aïssi-Rothe L; Virion JM; De Carvalho Bittencourt M; Ulas N; Audonnet S; Salmon A; Clement L; Venard V; Jeulin H; Stoltz JF; Decot V; Bensoussan D
Cytotherapy; 2014 Jan; 16(1):122-34. PubMed ID: 24094498
[TBL] [Abstract][Full Text] [Related]
38. Priming of protective T cell responses against virus-induced tumors in mice with human immune system components.
Strowig T; Gurer C; Ploss A; Liu YF; Arrey F; Sashihara J; Koo G; Rice CM; Young JW; Chadburn A; Cohen JI; Münz C
J Exp Med; 2009 Jun; 206(6):1423-34. PubMed ID: 19487422
[TBL] [Abstract][Full Text] [Related]
39. CD4+ T-cell effectors inhibit Epstein-Barr virus-induced B-cell proliferation.
Nikiforow S; Bottomly K; Miller G
J Virol; 2001 Apr; 75(8):3740-52. PubMed ID: 11264363
[TBL] [Abstract][Full Text] [Related]
40. Immune escape by Epstein-Barr virus (EBV) carrying Burkitt's lymphoma: in vitro reconstitution of sensitivity to EBV-specific cytotoxic T cells.
Masucci MG; Zhang QJ; Gavioli R; De Campos-Lima PO; Murray RJ; Brooks J; Griffin H; Ploegh H; Rickinson AB
Int Immunol; 1992 Nov; 4(11):1283-92. PubMed ID: 1282031
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
